ARCHIVES

Fox Chase-Penn Program Wins Comprehensive Designation; OMB Tries To Limit Number to 21

This article is from The Cancer Letter archive.

Vol. 01 No. 36 | October 11, 1974

Download PDF Visit The Full Archive

Related Articles

Pathology Review Confirms Reserpine As Carcinogen

March 14, 1980

Clinical Trials Approved By NCI

January 30, 2004

June Panel Meeting Dropped

June 3, 1977

World Conference To Consider Smoking Problem, Research, Action

March 14, 1975

“Spoiled, Petulant Brat”: BioMarin CEO Fires Off Feisty Emails In Battle Over Access to PARP Inhibitor

November 8, 2013

Conversation with The Cancer Letter: McKinsey Charge: Create Plan To Expand MD Anderson’s Reach

February 7, 2014